3-Ethoxychromen-2-one | 65216-93-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 3-Ethoxychromen-2-one
• CAS: 65216-93-5
• 化学式: C₁₁H₁₀O₃
• 分子量: 190.19
• InChiKey: PPGXDBJURPEKDZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Novel Compounds
  申请人：Theoclitou Maria-Elena

  公开号：US20080004302A1

  公开（公告）日：2008-01-03

  There is provided a compound of formula (I): processes for the manufacture thereof, pharmaceutical compositions thereof and uses in therapy.

  提供了一个化合物，其化学式为(I)：制备方法、药物组合物以及在治疗中的用途。
• Loxapine analogs and methods of use thereof
  申请人：Edgar M. Dale

  公开号：US20060063755A1

  公开（公告）日：2006-03-23

  The invention relates to novel compounds and methods of using them for modulating sleep.

  这项发明涉及新化合物及其用于调节睡眠的方法。
• [EN] MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS<br/>[FR] MODULATION DE LA FERROPTOSE ET TRAITEMENT DES TROUBLES EXCITOTOXIQUES
  申请人：UNIV COLUMBIA

  公开号：WO2015084749A1

  公开（公告）日：2015-06-11

  The present invention provides, inter alia, a compound having the structure of Formula (I). Also provided are compositions containing a pharmaceutically acceptable carrier and a compound according to the present invention. Further provided are methods for treating or ameliorating the effects of an excitotoxic disorder in a subject, methods of modulating ferroptosis in a subject, methods of reducing reactive oxygen species (ROS) in a cell, and methods for treating or ameliorating the effects of a neurodegenerative disease.

  本发明提供了一种具有式（I）结构的化合物。还提供了含有药用载体和根据本发明的化合物的组合物。此外还提供了用于治疗或改善受体内兴奋毒性障碍影响的方法，用于调节受体内铁死亡的方法，用于减少细胞内活性氧化物种（ROS）的方法，以及用于治疗或改善神经退行性疾病影响的方法。
• [EN] PYRIMIDINEDIONE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRIMIDINEDIONE
  申请人：CONCERT PHARMACEUTICALS INC

  公开号：WO2009045476A1

  公开（公告）日：2009-04-09

  This invention relates to novel compounds that are pyrimidinedione derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel pyrimidinedione derivatives that are derivatives of alogliptin. This invention also provides compositions comprising one or more compounds of this invention and a carrier, and the use of the disclosed compound and compositions in methods of treating diseases and conditions that are beneficially treated by administering a dipeptidyl peptidase IV (DPP4) inhibitor.

  这项发明涉及一种新型化合物，即嘧啶二酮衍生物及其药用盐。更具体地说，这项发明涉及一种新型嘧啶二酮衍生物，它们是阿格列普汀的衍生物。该发明还提供了包含本发明中一种或多种化合物和载体的组合物，并且揭示了该化合物和组合物在治疗通过给予二肽基肽酶IV（DPP4）抑制剂有益治疗的疾病和症状的方法中的用途。
• THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS
  申请人：De Brabander Jef

  公开号：US20150232444A1

  公开（公告）日：2015-08-20

  The described invention provides small molecule anti-cancer compounds that selectively target and inhibit measurable biological activity of truncated APC proteins, an immortalized Human Colonic Epithelial Cell (HCEC) model, and pharmaceutical compositions comprising at least one of the small molecule anti-cancer compounds and a pharmaceutically acceptable carrier.

  所述发明提供了选择性靶向和抑制截短APC蛋白的可测生物活性、一种免疫化的人结肠上皮细胞（HCEC）模型以及包含至少一种小分子抗癌化合物和一种药用载体的制药组合物。